Single-nucleotide polymorphism associations with efficacy and toxicity in metastatic castration-resistant prostate cancer treated with cabazitaxel

Simple item page
dc.contributor.authorHerrero Rivera, Daniel
dc.contributor.authorGarrigós Vacas, Carmen
dc.contributor.authorMarcos Kovandzic, Laura
dc.contributor.authorPuente Vazquez, Javier
dc.contributor.authorAlonso, Lucía A.
dc.contributor.authorMellado González, Begoña
dc.contributor.authorGrande, Enrique
dc.contributor.authorLuque Caro, Raquel
dc.contributor.authorVirizuela Echaburu, Juan A.
dc.contributor.authorRodríguez Moreno, Juan F.
dc.contributor.authorEtxebarria, Ainara A.
dc.contributor.authorRodríguez Antona, Antona
dc.contributor.authorDurán, Ignacio
dc.date.accessioned2022-08-03T06:20:07Z
dc.date.available2022-08-03T06:20:07Z
dc.date.issued2022
dc.description.abstractBackground: The aim of this study was to evaluate the impact of certain single-nucleotide polymorphisms (SNPs) in cabazitaxel activity and toxicity in patients with metastatic castration-resistant prostate cancer (mCRPC). Patients & methods: 56 SNPs in five genes (CYP3A4, CYP3A5, ABCB1, TUBB1 and CYP2C8) were genotyped in 67 mCRPC patients and their correlation with outcomes analyzed. Results:TUBB1-rs151352 (hazard ratio: 0.52) and CYP2C8-rs1341164 (hazard ratio: 0.53) were associated with better overall survival, and CYP2C8-rs1058932 with biochemical progression (odds ratio: 6.60) in multivariate analysis. ABCB1-rs17327624 correlated with severe toxicity ≥ grade 3 (odds ratio: 8.56) and CYP2C8-rs11572093 with asthenia (odds ratio: 8.12). Conclusion: Genetic variants in mCRPC patients could explain different outcomes with cabazitaxel. Nonetheless, the small sample size and the high number of SNPs analyzed mean that the results are only hypothesis-generating and require further validation.spa
dc.description.filiationUEMspa
dc.description.impact2.1 Q4 JCR 2022spa
dc.description.impact0.435 Q3 SJR 2022spa
dc.description.impactNo data IDR 2022spa
dc.description.sponsorshipConsejería de Salud de la Junta de Andalucía (PI-0286-2014)spa
dc.identifier.citationRivera, D. H., Vacas, C. G., Kovandzic, L. M., Vázquez, J. P., Alonso, L. A., González, B. M., Aragón, V. C., Grande, E., Caro, R. L., Virizuela Echaburu, J. A., Rodríguez Moreno, J. F., Etxebarria, A. A., Rodríguez-Antona, C., & Durán, I. (2022). Single-nucleotide polymorphism associations with efficacy and toxicity in metastatic castration-resistant prostate cancer treated with cabazitaxel. Pharmacogenomics, 23(11), 627-638. https://doi.org/10.2217/pgs-2022-0023spa
dc.identifier.doi10.2217/pgs-2022-0023
dc.identifier.issn1462-2416
dc.identifier.urihttp://hdl.handle.net/11268/11560
dc.language.isoengspa
dc.peerreviewedSispa
dc.relation.publisherversionhttps://doi.org/10.2217/pgs-2022-0023spa
dc.rights.accessRightsrestricted accessspa
dc.subject.otherNeoplasias de la próstataspa
dc.subject.otherFarmacocinéticaspa
dc.subject.unescoGenéticaspa
dc.subject.unescoCáncerspa
dc.subject.unescoFarmacologíaspa
dc.titleSingle-nucleotide polymorphism associations with efficacy and toxicity in metastatic castration-resistant prostate cancer treated with cabazitaxelspa
dc.typejournal articlespa
dspace.entity.typePublication

Files

Collections

Otras Áreas de Investigación de Salud